We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+1.73%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$124M
AUM Growth
-$34.4M
Cap. Flow
-$23.6M
Cap. Flow %
-19.02%
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
14
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
INO icon
Inovio Pharmaceuticals
INO
+$4.65M
2
TELA icon
TELA Bio
TELA
+$3.5M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$3.18M
4
IKT icon
Inhibikase Therapeutics
IKT
+$2.82M
5
OPTN
OptiNose
OPTN
+$1.84M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$11.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$7.77M
3
RPRX icon
Royalty Pharma
RPRX
+$6M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.3M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
51
Amarin Corp
AMRN
$299M
$55.4K 0.04%
+5,713
New +$61.2K
ARQT icon
52
Arcutis Biotherapeutics
ARQT
$3.36B
– –
-88,457
Closed -$823K
RIGL icon
53
Rigel Pharmaceuticals
RIGL
$681M
– –
-309,100
Closed -$5M
RPRX icon
54
Royalty Pharma
RPRX
$25.9B
– –
-212,000
Closed -$6M
TENX icon
55
Tenax Therapeutics
TENX
$363M
– –
-50,000
Closed -$173K
FNA
56
DELISTED
Paragon 28, Inc.
FNA
– –
-114,724
Closed -$766K
VIRX
57
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-500,000
Closed -$116K
1 2
3

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Stonepine Capital Management held 58 positions worth $124M, down 22% from $158M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management withdrew a net $23.6M in Q4 2024, closing 6 positions and reducing 17 holdings. Its most notable exit was Royalty Pharma, an estimated $6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Inovio Pharmaceuticals worth $1.92M.

  • Stonepine Capital Management's largest Q4 2024 buy was Inovio Pharmaceuticals: 1,050,000 shares worth $1.92M.
  • Stonepine Capital Management added most to TELA Bio in Q4 2024, an estimated $3.5M increase.
  • Stonepine Capital Management's biggest Q4 2024 reduction was ADMA Biologics, cutting an estimated $11.8M.
  • Stonepine Capital Management fully exited Royalty Pharma in Q4 2024, selling an estimated $6M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $124M portfolio in Q4 2024.
  • Stonepine Capital Management opened 20 new positions and closed 6 in Q4 2024.
  • Stonepine Capital Management's portfolio value fell 22% quarter-over-quarter to $124M.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.